CAR-NK 细胞治疗癌症患者：已发表研究与注册临床试验的系统范围综述

A systematic review of all publications (to January 25, 2025) and registered clinical trials (to June 21, 2024) was conducted. We extracted information on study design, patient characteristics, outcome measures, and cell product characterization.

A total of 150 patients in ten studies published between 2018 and 2025 were identified. Hematologic malignancies were examined most frequently (n = 6 studies). All published studies were uncontrolled, and only four reported on more than three patients. CAR-NK products were most frequently derived from the NK-92 cell line (four studies), umbilical cord blood (three studies), induced pluripotent stem cells (one study), or not reported (two studies). Considerable heterogeneity was observed regarding CAR-NK cell manufacturing methods and dosing. Complete response rates for patients with B cell lymphomas ranged from 25-85%, depending on lymphoma subtype. Responses were durable with median response not reached in the largest study and durable remission at 1-year in 70% of responders in a second study. Adverse events were uncommon with no cases of grade 3 or higher cytokine release syndrome and no cases of immune effector-cell mediated neurotoxicity or graft versus host disease reported. Among the 50 registered trials identified (n=2102 subjects to be enrolled), hematological malignancies (n = 34; 68%) were the most common diseases examined.

The clinical outcomes and low adverse event rates following CAR-NK therapy in published studies are encouraging. Larger controlled trials are needed to confirm the safety and efficacy of CAR-NK therapy. We anticipate the completion of several such trials in the coming years.